Patient Characteristics

Whole group

AGE

53 (26 - 79 yrs)

SEX

Male

Female

18 (90%)

2 (10%)

ECOG (PS)

0 - 1

>2

14 (70%)

6 (30%)

Metastatic Sites

1

≥2

7 (35%)

13 (65%)

Line of Immunotherapy

1^st line

≥2 line

6 (30%)

14 (70%)

ADRs with Immunotherapy

No toxicity

Toxicity

14

6 (Anaemia)

AVG Duration of Immunotherapy

(3 - 6 cycles)

Response rate (3 - 6 cycles)

PR

SD

PD

3

5

12